Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-12-04

Clinical Trial Update: Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing etoricoxib 30 mg to celecoxib 200 mg in Korean participants with osteoarthritis shows safety and efficacy data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Celecoxib (Celecoxib)
  • Etoricoxib (etoricoxib)

Snippet

Sponsor: Organon and Co | Conditions: Osteoarthritis of the Knee | Phase 3 | Status: COMPLETED | Results posted: 2013-12-04